Genzyme Corp. (Nasdaq: GENZ) announced that its second phase 3 trial of Mozobil has successfully met its primary and secondary ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE